PHASE II TRIAL OF CELECOXIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KHODADAD K.; ABD ELAH SHAMSHIRSAZ A.R.; AZADI A.; MOSTOUFI A.N.; TAHBAZ M.O.; EMAMI H.; KARIMI SH.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: TANAFFOS Year:2007 | Volume:6 | Issue:1 (21) Page(s): 37-46

Download Full-Text

View:

268

Download:

102

Cites:

Information Journal Paper

Title

PHASE II TRIAL OF CELECOXIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER

Author(s)

Keywords

NON-SMALL CELL LUNG CANCER

CELECOXIB

PACLITAXEL

CARBOPLATIN

Abstract

Background: Prostaglandins (PGs) can enhance tumor growth and metastasis by stimulating angiogenesis and invasiveness, in addition to apoptosis and immune surveillance. Microtubule-interfering agents induce cyclooxygenase-2 (COX-2) and PG biosynthesis and this might reduce the efficacy of PACLITAXEL. Preclinical studies suggest that treatment with a selective COX-2 inhibitor may augment the antitumoral effects of chemotherapy. Thus, we designed a phase II trial to evaluate the efficacy of the combination of PACLITAXEL, CARBOPLATIN and CELECOXIB in advanced NON-SMALL CELL LUNG CANCER.Materials and Methods: Thirty-seven patients were enrolled in this trial. The inclusion criteria were: chemotherapy-naïve advanced NSCLC (non-resectable locally advanced stage IIIA, stage IIIB and IV), age> 18 yrs. and performance status (PS) of 0-2 (ECOG). All patients were given PACLITAXEL (200 mg/m2) and CARBOPLATIN (AVC 6) on day 1, every 21 days and CELECOXIB (400 mg) daily.Results: Most of the patients were male and the mean age was 58 yrs. Old. Performance status 0, 1, and 2 were 8.2%, 40.5% and 51.3%, respectively. Four patients were in stage /IIA (10.8%), 12 patients in stage /IIB (32.4%) and 21 (56.8%) in stage IV. The overall response rate was 54%. Time to progression and median overall survival were 5.7 and 9 months, respectively. Only one patient had grade 3 anemia. There was no grade 4 cytotoxicity. Three patients had cytotoxic drug allergy.Conclusion: Based on this study, adding 400 mg CELECOXIB to the standard regimen (paclitaxel plus CARBOPLATIN) does not enhance time to progression and overall survival compared to historical data. Thus, we recommend combining higher dosage of CELECOXIB with other targeted agents in phase I/II trials.

Cites

No record.

References

No record.

Cite

APA: Copy

KHODADAD, K., ABD ELAH SHAMSHIRSAZ, A.R., AZADI, A., MOSTOUFI, A.N., TAHBAZ, M.O., EMAMI, H., & KARIMI, SH.. (2007). PHASE II TRIAL OF CELECOXIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER. TANAFFOS, 6(1 (21)), 37-46. SID. https://sid.ir/paper/584979/en

Vancouver: Copy

KHODADAD K., ABD ELAH SHAMSHIRSAZ A.R., AZADI A., MOSTOUFI A.N., TAHBAZ M.O., EMAMI H., KARIMI SH.. PHASE II TRIAL OF CELECOXIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER. TANAFFOS[Internet]. 2007;6(1 (21)):37-46. Available from: https://sid.ir/paper/584979/en

IEEE: Copy

K. KHODADAD, A.R. ABD ELAH SHAMSHIRSAZ, A. AZADI, A.N. MOSTOUFI, M.O. TAHBAZ, H. EMAMI, and SH. KARIMI, “PHASE II TRIAL OF CELECOXIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER,” TANAFFOS, vol. 6, no. 1 (21), pp. 37–46, 2007, [Online]. Available: https://sid.ir/paper/584979/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops